Arcadia sgr, through its Arcadia Small Cap fund, and Futurimpresa sgr, through its Finanza e Sviluppo Impresa fund, acquired the entire shareholders capital of Lisapharma, a leading injectable generic drugs maker based in Erba (Como) (download herei the press release).
Seller was the founder familiy Zagnoli and  the deal has been totally financed by equity. After the deal the company is now controlled by Arcadia (with a 53.7% stake), while Futurimpresa owns a 44.3% stake and the new managers Giovanni Franchi (chairman) and Massimiliano Del Frate (ceo) own the remaining 2% stake.
Founded in 1925, Lisapharma, reached 28 million euros in revenues last year, of which more than 80% coming from exports.
This is the forth deal in the pharma sector in few months in Italy. Few days ago Progressio sgr and Idea Capital Funds sgr signed yesterday the acquisition of the whole capital of Italchimici spa, a Rome-based company specialized in distribution of ethical drugs and integrators (see here a previous post by BeBeez),
A few days before Trilantic Capital Europe announced it had bought 90% of the capital of Doppel Farmaceutici, a leading Italian company active in pharmaceutical research, development, formulation, manufacturing and packaging, in outsourcing only (see here a previous post by BeBeez).
Finally last April Wise sgr announced it had bought an 84.75% stake in NTC, a generic drugs and nutraceuticals products maker. Wise  had bought PH&T, another generic pharma maker, last january.
